{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Bell M"],"funding":["Bill and Melinda Gates Foundation (GF)","World Health Organization","European Research Council","University of Antwerp (DOCPRO4-TT(ZAP)BOF)","Fonds Wetenschappelijk Onderzoek (FWO)"],"pagination":["e0140424"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11837537"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["63(2)"],"pubmed_abstract":["Despite first-void urine (FVU) being increasingly recognized as a credible specimen for human papillomavirus (HPV) detection, there is a lack of well-validated testing methods providing full quantitative genotyping required for vaccine impact monitoring from FVU samples. The Allplex HPV28 assay, capable of individually detecting 28 HPV genotypes, presents a promising method. We aimed to evaluate its genotype-specific performance on FVU samples, following optimization of FVU preanalytics. We selected 701 FVU samples collected using a Colli-Pee device (20 mL, with UCM), enriched for HPV-positivity (<i>n</i> = 630) based on previous testing with GP5+/6+-PCR-based reverse line blot (GP5+/6+ RLB) and E7-MPG after Amicon filtration (AF). We first evaluated the comparability and agreement of Allp"],"journal":["Journal of clinical microbiology"],"pubmed_title":["Optimization and analytical validation of the Allplex HPV28 genotyping assay for use in first-void urine samples."],"pmcid":["PMC11837537"],"funding_grant_id":["35537","001","OPP1053353","101040588","FN542300005","11PJK24N"],"pubmed_authors":["Tenet V","Heideman DAM","Gheit T","Bell M","Clifford G","Van Caesbroeck A","Rol M","Vorsters A","Baussano I"],"additional_accession":[]},"is_claimable":false,"name":"Optimization and analytical validation of the Allplex HPV28 genotyping assay for use in first-void urine samples.","description":"Despite first-void urine (FVU) being increasingly recognized as a credible specimen for human papillomavirus (HPV) detection, there is a lack of well-validated testing methods providing full quantitative genotyping required for vaccine impact monitoring from FVU samples. The Allplex HPV28 assay, capable of individually detecting 28 HPV genotypes, presents a promising method. We aimed to evaluate its genotype-specific performance on FVU samples, following optimization of FVU preanalytics. We selected 701 FVU samples collected using a Colli-Pee device (20 mL, with UCM), enriched for HPV-positivity (<i>n</i> = 630) based on previous testing with GP5+/6+-PCR-based reverse line blot (GP5+/6+ RLB) and E7-MPG after Amicon filtration (AF). We first evaluated the comparability and agreement of Allp","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Feb","modification":"2025-04-04T02:05:11.298Z","creation":"2025-04-04T02:05:11.298Z"},"accession":"S-EPMC11837537","cross_references":{"pubmed":["39723836"],"doi":["10.1128/jcm.01404-24"]}}